HB2 a candidate HDL receptor, is quite distinct from other HDL receptors in its structure. However, while changes in cellular cholesterol content, or a reduction in cholesterol biosynthesis accompany corresponding changes in HB2 expression, the level at which these changes occur have not been determined and the regulation and the function of HB2 remain uncertain.
Introduction
The incidence of premature artery wall disease is lowered in the presence of high levels of circulating high density lipoprotein (HDL) suggesting that HDL may protect individuals against atherosclerosis (1) . Part of this protection may be attributed to the participation of HDL in the reverse cholesterol transport pathway, a mechanism that reduces the accumulation of cholesterol in the arterial wall and the narrowing which subsequently occurs (2) . We have purified two proteins, HB1 and HB2 (HDL binding proteins 1 and 2), from rat liver (3) cloning HB2 and have reported its cDNA sequence and characterized some of its properties (4) . As a candidate HDL receptor, it is quite distinct from SR-BI or other HDL binding proteins previously reported (5, 6) , and shows significantly homology with the adhesion molecules ALCAM and BEN of the immunoglobulin superfamily (7, 8) .
The structure of HB2 comprises a 32-amino acid cytoplasmic domain, 24-amino acid hydrophobic transmembrane domain and approximately 500 residues of an extracellular domain terminating in the NH2 residues. When HB2 cDNA was transfected into HepG2 cells and Chinese hamster ovary cells (CHO cells), specific HDL3 binding activity increased by 80-100%.
THP-1 cells treated with phorbol 12-myristate 13-acetate (PMA) resulted in a striking increase in HB2 mRNA, an expression that was subsequently reduced by cholesterol loading the cells with acetyl LDL (4). These results suggested that, distinct from the properties of a cell adhesion molecule, HB2 may have an alternative role that is related to the cell lipid metabolism or processing of HDL, but the details of this lipid associated function of HB2 is not known as yet.
In order to further pursue a possibility (9) that cell cholesterol synthesis may be related to the expression of HB2, we have treated rabbits with simvastatin, an HMG CoA reductase inhibitor, and determined the effect of lowering cholesterol synthesis on HB2 expression.
Materials and Methods

Materials
Simvastatin was used as the lactone form transformed to the sodium salt of the hydroxy-acid (active form). All other chemicals used were of analytical grade.
Animals and diet
Twelve male Japanese white rabbits (average weight 3 kg) were purchased from Oriental Yeast Co. Ltd. (Tokyo , Japan) and fed a commercial chow, RC-4 pellet (Oriental Yeast Co Ltd.) throughout the experiments . Six rabbits were given 15 mg/kg of simvastatin by oral administration every day for 21 days and the remainder were given the same volume of saline as a control. Blood was taken from each rabbit by cardiac puncture under anesthesia by pentobarbital sodium (Abbott Laboratories, USA) after overnight fasting. Liver, lung, jejunum and brain were harvested for RNA extraction.
All the tissues were immediately transferred into liquid nitrogen for storage before the extraction of RNA as below.
Measurement of HB2 mRNA expression
Frozen tissue (200 mg) was broken into small pieces and homogenized in 5 M of guanidium thiocyanate solution using a polytron homogenizer.
Total RNA was prepared as described elsewhere (10). Fifteen micrograms of total RNA was isolated by 1% agarose gel electrophoresis including formamide, transferred to a nylon membrane The liver cholesterol concentration was significantly suppressed by 25% compared with control. The cholesterol concentration of the lung had a tendency of reduction but there was no significant difference. Fig.  2(A) shows the expressions of HB2 mRNA in the liver, lung, jejunum and brain of rabbits hybridized with rat HB2 cDNA probe. The data showed that the rat HB2 cDNA was also available to detect rabbit HB2 mRNA levels. Northern (A) (B) ut did not produce changes in the jejunum and brain ( Fig .  5A and B) . Fig. 4 . HB2 expression and the effect of simvastatin . Rabbits were treated with simvastatin or saline (Control) for 21 days. Total RNA was prepared from liver (A) and lung (B) and fractionated by 1% agarose gel electrophoresis . RNA blots were probed with 32P-labeled HB2 and GAPDH cDNA and the intensity was measured by BAS 2000 (Fuji Film Co) . HB2 mRNA levels were expressed as the ratio of pixels to that of GAPDH. Values are mean +SD . Significant difference from Control, * ; p < 0.05, ** ; p < 0 .01 (n = 6) 
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Discussion HB2 is one of two candidate HDL receptors purified from rat and human liver (3) and has been cloned and sequenced (4). Mathai et a!. (9) reported previously that the binding activities of HB1 and HB2 were reduced significantly in the livers of rats fed simvastatin alone or simvastatin with cholestyramine, using ligand blot analysis. Having postulated that the decrease in binding activity was most likely due to a decrease in expression of HB2 protein that followed a reduction in cholesterol synthesis or as a direct result of simvastatin, we sought clarification of the regulative process by measuring HB2 mRNA levels in various rabbit tissues after treating the animals with simvastatin.
The results of the present study essentially confirm the previous finding (9) but in addition show that the reduction in HB2 follows a corresponding down-regulation of HB2 mRNA in response to simvastatin.
This response was most evident in the liver and lung, with little change seen in either the brain or jejunum. The data suggest that in the lung and liver, biochemical events following statin treatment lead to transcriptional regulation of HB2. The changes in HB2 expression accompanied a lowering of HDL cholesterol by approx 33% and VLDL+ LDL cholesterol by approx 50%. Whether or not these changes in plasma lipids influenced the regulation of HB2 (and HB1) is unknown but an alternative suggestion, that simvastatin acting through cellular pathways influences transcription of HB2 mRNA and subsequently, HB2 levels, appears more likely. A positive correlation between HDL-cholesterol and HB2 mRNA levels suggests that HB2 is one of many factors that regulate plasma HDL-cholesterol levels. Although the function of HB2 is not known, HB2 may regulate cellular cholesterol by inhibiting cholesterol efflux from the liver when cholesterol synthesis is downregulated.
HMG CoA reductase inhibitors are known to increase HDL cholesterol levels in humans (12-14), while they appear to decrease not only total cholesterol but also HDL-cholesterol in most experimental animals (15-17). In this study, rabbits were fed a normal diet without additional cholesterol during the experimental period. The ratio of HDL-cholesterol to total cholesterol was higher in the simvastatin treated group, although HDL cholesterol per se tended to be decreased by simvastatin.
Meijer et al. (18) reported that simvastatin lowered serum cholesteryl ester transfer protein (CETP) but not lecithin : cholesterol acyltransferase (LCAT) in rabbit, so it is possible that the rise in proportion of plasma HDL shown here may have been the result of lowered CETP activity, although a reduction in HDL binding to HB2 in tissues affected by simvastatin cannot be excluded and may have contributed to the rise.
We have reported that THP-1 cells treated with PMA resulted in a striking increase in HB2 mRNA and that this rise was reduced by cholesterol loading the cells with acetyl LDL (4) . Together with this data, the present studies suggest that HB2 levels may be related to changes in the cholesterol metabolism.
These functions are distinct from those related to uptake of cholesterol ester (19) and cholesterol efflux that are mediated by SR-BI (20).
The evidence implicating HB2 (and HB1) in HDL physiology arose from observations that both these membrane proteins bound HDL and apoAl or apoAll, but not LDL, in ligand blot studies (3) . In a more recent study, it was also shown that human monocytes specifically bind HDL and apoAl, and that there is a strong positive correlation between monocyte HB2 and circulating HDL (21). Additionally, we have recently identified a domain on the extracellular region of HB2 that specifically binds HDL or apoAl, but not LDL (unpublished observations), strengthening evidence for a role of HB2 in some cellular pathway that is influenced by interaction with HDL or its apoprotein moieties. The present study has shown that, either through a direct effect on transcription or via changes in sterol biosynthesis following statin treatment, HB2 expression is down regulated, encouraging further investigation of its role in lipid metabolism.
